Spannerwerks
- Company typePrivate
- Founded2020
- HeadquartersSeattle, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Spannerwerks does
Spannerwerks is a Seattle-based drug development consulting firm that deploys a consortium of senior subject-matter experts and project managers to pharmaceutical and biotechnology companies at critical inflection points in the drug development lifecycle — including IND and BLA filings, clinical study start-ups, CMC program management, and commercial launch readiness. The firm sells time and expertise rather than a software platform; its delivery model is to embed consultants inside client organizations, integrating with internal teams and flexing up or down as project needs dictate. Revenue is generated through professional-services engagements, with pricing tied to project scope and duration rather than a standardized fee schedule.
The firm was founded in 2015 and rebranded in 2020 around the tagline 'Experience | Expertise | Execution,' coinciding with its public repositioning and initial case-study marketing. The leadership team comprises four named principals — CEO Dara Lockert, Chief Business Officer Brian Miller, Director of Product Development Consulting Lori Hansen (PhD), and Director of CMC Technical Consulting Patsy Lewis — each with 25+ years of biopharma experience spanning biologics, gene therapy, immunotherapy, genomics, and vaccines. Documented engagements include IND completion in nine months for a university-backed immune-oncology startup, CMC and quality program management enabling on-schedule BLA filing during COVID-19, and commercial-launch team streamlining for a mid-market biopharma that was subsequently acquired.
On October 23, 2025, Spannerwerks was acquired by Alloy Therapeutics and operates as a wholly-owned subsidiary within Alloy's broader R&D services platform. Pre-acquisition, the firm operated as a private LLC with 1–10 employees, direct B2B sales motion, no disclosed funding, no patents or proprietary technology assets, and no AI/ML component to its offering.
Spannerwerks firmographics
Firmographics- Name
- Spannerwerks
- Legal name
- Spannerwerks, LLC
- Website
- https://spannerwerks.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Spannerwerks industry classification
Industry- Product category
- Pharmaceutical Drug Development Consulting
- NAICS
- Other Scientific and Technical Consulting Services (541690), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Trial Site Operations & Study Coordination (HLAGACAE)
- akta.pro secondary industries
- Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Site Identification & Feasibility (HLAGACAB)
Keywords
Where Spannerwerks is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Spannerwerks business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales
Revenue model
- Drug Development Consulting Services: Professional services revenue generated through consulting engagements with pharmaceutical and biotech companies. Services include project management, subject matter expertise, and integrated program management throughout the drug development lifecycle from preclinical to commercial launch.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Spannerwerks product offering
Product offeringCore offering
Spannerwerks provides a consortium of experienced project management professionals and subject matter experts to pharmaceutical and biotech companies throughout the drug and biologic development lifecycle. Services span IND filing support, clinical trial initiation and management, CMC technical consulting, regulatory submission support, and commercial launch readiness, with experts embedded in client teams during critical inflection points.
Product overview
Spannerwerks is a drug development consulting firm offering a consortium of experienced project management professionals and subject matter experts. The company provides flexible consulting services across all phases of drug and biologic development and commercialization, including IND filing support, clinical trial management, CMC technical consulting, program management, and commercial launch readiness. Their model allows clients to engage experts as needed to fill organizational gaps during critical inflection points such as filing INDs, starting studies, or commercializing new products.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Development Consulting Services A consortium of experienced project management professionals and subject matter experts providing support throughout the drug development process, including IND filing, clinical trial management, CMC consulting, and commercial launch readiness for pharmaceutical and biotech companies.
Quantifiable outcome
- FDA filing completed in 9 months including GMP tech transfer and final clinical protocol
- +2 more outcomes
Companies that use Spannerwerks
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles1 record
Spannerwerks technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Spannerwerks partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- Alloy TherapeuticsflagshipAlloy Therapeutics acquired Spannerwerks to expand its capabilities in drug development and support partners through the entire R&D lifecycle. The acquisition brings Spannerwerks' consulting expertise in drug development under Alloy's broader platform, enhancing end-to-end R&D services for biotechnology and pharmaceutical partners.
- BioEclipse TherapeuticscoreSpannerwerks collaborated with BioEclipse Therapeutics to prepare for Phase 1 clinical trial for CRX100, a cancer immunotherapy candidate. Spannerwerks worked with BioEclipse to complete the IND filing for CRX100, providing executive director oversight and program management expertise. The collaboration successfully advanced this innovative immunotherapy from the laboratory into clinical trials.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
Spannerwerks competitors and assessment
Company assessmentDirect peers
- Halloran Consulting Group: Boston-based drug development consulting firm providing program leadership, regulatory, and CMC advisory to biotech and pharma. Closely comparable to Spannerwerks in service mix, target customer (early- to mid-stage biotech), and senior-consultant-led delivery model.
- Dark Horse Consulting: Specialist cell and gene therapy consulting firm supporting CMC, manufacturing, and regulatory strategy. Highly comparable in modality focus and boutique senior-expert positioning, with overlap on gene therapy and immunotherapy clients served by Spannerwerks.
- ProPharma Group: Pharmaceutical consulting and compliance services firm covering regulatory affairs, clinical research, and quality/compliance. Comparable to Spannerwerks in serving pharma/biotech at development and commercialization inflection points with project-based engagements.
- NDA Group: Regulatory and drug development consultancy serving pharma and biotech with submission strategy, dossier preparation, and product development advisory. Direct overlap with Spannerwerks' regulatory and CMC work and small/mid-cap biotech client base.
- Camargo Pharmaceutical Services: Drug development consultancy specializing in 505(b)(2), ANDA, and biologics development strategy and submissions. Comparable to Spannerwerks in the sponsor-side program management niche and serving similar biotech and mid-market pharma customers.
- Lachman Consultants: Pharmaceutical consulting firm focused on CMC, regulatory compliance, and technical operations for drug development and commercial manufacturing. Directly comparable to Spannerwerks' CMC consulting line of service and enterprise pharma engagement profile.
Broad incumbents
- Charles River Associates: Global management consultancy with a life sciences practice offering commercial, clinical, and regulatory strategy to large pharma and biotech. Wider portfolio and larger bench than Spannerwerks, but competes for the same strategy and program leadership mandates.
Others
- ZS Associates: Global management consulting firm serving pharma and biotech on commercial strategy, launch, and R&D operations. Overlaps with Spannerwerks on commercial launch readiness engagements for biopharma clients, but at much greater scale and broader service scope.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Spannerwerks social profiles
Digital presenceSpannerwerks financial estimates
Financial estimateRevenue estimate
Valuation estimate
Spannerwerks leadership team
Management profileNumber of profiles
Profiles4 records
Spannerwerks funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Spannerwerks M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Spannerwerks
What does Spannerwerks do?
Spannerwerks provides a consortium of experienced project management professionals and subject matter experts to pharmaceutical and biotech companies throughout the drug and biologic development lifecycle. Services span IND filing support, clinical trial initiation and management, CMC technical consulting, regulatory submission support, and commercial launch readiness, with experts embedded in client teams during critical inflection points.
Is Spannerwerks a public or private company?
Spannerwerks is a private company. It is classified as corporate owned and is currently acquired.
When was Spannerwerks founded?
Spannerwerks was founded in 2020. It employs 1 to 10 people.
Where is Spannerwerks based?
Spannerwerks is headquartered in Seattle, United States, in the North America region.
How does Spannerwerks make money?
One revenue line is on record: drug Development Consulting Services.
Who are Spannerwerks's main competitors?
Direct peers on record are Halloran Consulting Group, Dark Horse Consulting, ProPharma Group, NDA Group, Camargo Pharmaceutical Services and Lachman Consultants. Charles River Associates is listed as a broad incumbent. ZS Associates is listed as an others.
Does Spannerwerks have an API?
No public API is recorded for Spannerwerks.
What industry is Spannerwerks in?
Spannerwerks's product category is Pharmaceutical Drug Development Consulting. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination, with a secondary code of HLAGACAG, Clinical Trial Monitoring Support (On-site/Remote). Its NAICS code is 541690 and its SIC code is 8742.